Research
Radiobiology and Targeted Radiotherapy : JP. Pouget

SUMMARY

Our team is developing a streamlined approach in preclinical targeted radiotherapy for translational purposes. It consists of researchers and clinicians from nuclear medicine. TRT consists of treating cancer by the administration of radiolabelled molecules called radiopharmaceuticals. These radiopharmaceuticals are composed of a vector molecule (monoclonal antibody, peptide, etc.) targeting the tumor cells or their environment and of a radionuclide that decays by emitting ionizing radiation. The therapeutic activity of the radiopharmaceutical can be due to both the biological action of the carrier molecule and the effects of irradiation. These radiopharmaceuticals can also be developed for diagnostic purposes to detect tumor cells in the body. For this, the carrier molecule must be adapted and the radionuclide must emit detectable radiation by SPECT and PET molecular imaging techniques. The approach associating the same targeting molecule for diagnosis and therapy is called theranostic. The rationalization of our approach focuses on establishing dose-response relationships between administered activities and observed biological effects (therapeutic efficacy / toxicity). It therefore requires knowledge of the biological mechanisms involved (radiobiology) and the control of doses delivered (dosimetry). Our work focuses on the role of targeted (radiative) and non-targeted (bystander and abscopal) effects involving intercellular communications and / or the involvement of the immune system. The final aim of our research, led by a multidisciplinary team, is to be transferred to the clinic for optimal cancer diagnosis and treatment.

Publications

Ladjohounlou R, Lozza C, Pichard A, Constanzo J, Karam J, Le Fur P, Deshayes E, Boudousq V, Paillas S, Busson M, Le Blay M, Jarlier M, Marcatili S, Bardiès M, Bruchertseifer F, Morgenstern A, Torgue J, Navarro-Teulon I, Pouget J-P Drugs that modify cholesterol metabolism alter the p38/JNK-mediated targeted and non-targeted response to alpha and Auger radioimmunotherapy. Clin. Cancer Res.. May 06, 2019. doi:10.1158/1078-0432.CCR-18-3295

Pouget J-P, Georgakilas A, Ravanat J-L Targeted and Off-Target (Bystander and Abscopal) Effects of Radiation Therapy: Redox Mechanisms and Risk/Benefit Analysis. Antioxid. Redox Signal.. 2018;29(15):1447-1487. doi:10.1089/ars.2017.7267

Deshayes E, Ladjohounlou R, Le Fur P, Pichard A, Lozza C, Boudousq V, Sevestre S, Jarlier M, Kashani R, Koch J, Sosabowski J, Foster J, Chouin N, Bruchertseifer F, Morgenstern A, Kotzki P-O, Navarro-Teulon I, Pouget J-P Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer. J. Nucl. Med.. 2018;59(8):1234-1242. doi:10.2967/jnumed.118.208611

Paillas S, Ladjohounlou R, Lozza C, Pichard A, Deshayes E, Jarlier M, Sevestre S, Le Blay M, Boudousq V, Sosabowski J, Chardes T, Teulon I, Mairs R, Pouget J Localized irradiation of cell membrane by Auger electrons is cytotoxic through oxidative stress-mediated non-targeted effects. Antioxidants & redox signaling. May 25 2016. doi:10.1089/ars.2015.6309


Team

Team Leader  :  Jean-Pierre Pouget

Institut de Recherche en
Cancérologie de Montpellier
Campus Val d’Aurelle
34298 Montpellier cedex 5

 

Tél. : 33 (0)4 67 61 37 08
Fax : 33 (0)4 67 61 37 87
jean-pierre.pouget@inserm.fr

 

Partners / Funding


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés